Skip to search formSkip to main contentSkip to account menu

DiaCIM

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience.
  • J. Spicer
  • Current opinion in molecular therapeutics (Print)
  • 2005
  • Corpus ID: 27175085
A joint venture between YM BioSciences (formerly York Medical) and The Center of Molecular Immunology is collaborating with… 
2002
2002
A phase I study of 99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptor
A phase I trial was conducted to evaluate the safety, tumour and normal tissue localization, pharmacokinetics and radiation… 
2002
2002
Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
The use of antibodies as targeting agents for the delivery of radioisotopes to tumors is a promising concept that has received… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)